Six cycles of platinum-based chemotherapy followed by avelumab continues to be used in some circumstances in advanced/metastatic urothelial cancer (mUC). To investigate whether shorter chemotherapy duration improves quality of life (QoL) without worsening efficacy, this study compared 3 vs 6 cycles followed by avelumab.
Three versus six cycles of platinum-based chemotherapy followed by avelumab maintenance as first-line treatment for advanced urothelial cancer: the phase II DISCUS trial
Annals of Oncology | | T. Powles, S.A. Hussain, M.A. Climent, I.G. Carbonero, J. Molina-Cerrillo, J. Puente, P. Borrega, J. Malik, L-M Dourthe, R. Jones, D. Castellano, I. Durán, Y. Loriot, G. Priyadarshini, B. Szabados, F. Jamal, Y.Q. Wang, N. Kotriwala, F. Jackson-Spence, C. Ackerman, E. Grande
Topics: chemotherapy, clinical-trials, research